FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3166050902> ?p ?o ?g. }

• W3166050902 endingPage "e21215" @default.
• W3166050902 startingPage "e21215" @default.
• W3166050902 abstract "e21215 Background: Indoleamine 2, 3-dioxygenase (IDO), a known immunoinhibitory enzyme, plays an important role on tumor metastasis through manipulation of host immune status. We have demonstrated that IDO level has prognostic value and low IDO level is associated with low risk of distant metastasis in patients with non-small cell lung cancer (NSCLC). However, the association between IDO immune status in patients with brain metastasis (BrM) is unknown. We hypothesized that the IDO1 activity are different in the NSCLC patients of various stages and in patients with or without BrM and the IDO mRNA expression in brain metastatic lesion differ from the primary tumor or metastasized regional lymph nodes. Methods: This was part of a prospective study of blood immune biomarkers for prognosis and prediction. Newly diagnosed or recurrent NSCLC patients were eligible. Blood samples were obtained before treatment start and plasma were used for the Kynurenine (Kyn) and tryptophan (Trp) measurement by the high-performance chromatography. Kyn and trp was detected with more than 95% re-productivity. IDO activity was defined as ratio of kyn/Trp. Student T-test and One-way anova were applied for group comparison. CI: confidence interval. P < 0.05 was considered as statistical significance. The IDO cellular expression was analyzed by the http://ureca-singlecell.kr/ website tool using the GEO dataset GSE131907. Results: Between July 2019 and Dec 2020, a total of 121 patients with NSCLC were eligible. The mean concentration of Kyn was 1.69 uM in patients with stage IV (n = 60, CI: 1.38-2.00), compared with 1.57 in patients with stage I (n = 38, CI: 1.03-2.10), 1.63 in stage II (n = 13, CI: 1.03-2.23) and 2.01 in stage III (n = 10, CI: 0.72-3.30, mean = 2.01). The mean ratio of Kyn:Trp was 0.10 in stage IV (n = 60, CI: 0.07-0.12), compared with 0.13 in patients with stage I (n = 38, CI: 0.06-0.20), 0.15 in stage II (n = 13, CI: 0.03-0.29) and 0.15 in stage III (n = 10, CI: 0.12-0.29). In patients with stage IV, there was no significant difference in the kyn concentration in patients with BrM (n = 13) and those without BrM (n = 47) (mean: 1.74, CI: 0.47-2.41 v.s 2.03 mean: 1.12-3.08; p = 0.45). The IDO activity in the patients with BrM was not significantly different from that of patients without BrM (mean: 0.11, CI: 0.03-0.20 v.s mean: 0.13, CI: 0.08-0.17; p = 0.74). Interestingly, GEO dataset analysis of the IDO1 mRNA expressions in 44 patients showed enrichments in myeloid cells in primary lung cancer tumor, natural killer cells in metastasized lymph nodes, and B cells in brain metastatic lesion. Conclusions: This study demonstrated no significant differences in circulating IDO expressions in patients with brain metastasis but differential IDO patterns of cellular expression in brain metastasis from that of primary tumor in NSCLC patients. This finding suggests the need of new strategy of research for immune status in the brain metastatic process of non-small cell lung cancer." @default.
• W3166050902 created "2021-06-22" @default.
• W3166050902 creator A5003746092 @default.
• W3166050902 creator A5030866090 @default.
• W3166050902 creator A5033229269 @default.
• W3166050902 creator A5037412714 @default.
• W3166050902 creator A5046868072 @default.
• W3166050902 creator A5050809443 @default.
• W3166050902 creator A5053029141 @default.
• W3166050902 creator A5053447705 @default.
• W3166050902 creator A5067295868 @default.
• W3166050902 creator A5071891964 @default.
• W3166050902 creator A5081533954 @default.
• W3166050902 creator A5085819924 @default.
• W3166050902 creator A5086753069 @default.
• W3166050902 creator A5087660180 @default.
• W3166050902 creator A5089700943 @default.
• W3166050902 date "2021-05-20" @default.
• W3166050902 modified "2023-10-01" @default.
• W3166050902 title "Association of IDO immune suppression with brain metastasis in non-small cell lung cancer." @default.
• W3166050902 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.e21215" @default.
• W3166050902 hasPublicationYear "2021" @default.
• W3166050902 type Work @default.
• W3166050902 sameAs 3166050902 @default.
• W3166050902 citedByCount "0" @default.
• W3166050902 crossrefType "journal-article" @default.
• W3166050902 hasAuthorship W3166050902A5003746092 @default.
• W3166050902 hasAuthorship W3166050902A5030866090 @default.
• W3166050902 hasAuthorship W3166050902A5033229269 @default.
• W3166050902 hasAuthorship W3166050902A5037412714 @default.
• W3166050902 hasAuthorship W3166050902A5046868072 @default.
• W3166050902 hasAuthorship W3166050902A5050809443 @default.
• W3166050902 hasAuthorship W3166050902A5053029141 @default.
• W3166050902 hasAuthorship W3166050902A5053447705 @default.
• W3166050902 hasAuthorship W3166050902A5067295868 @default.
• W3166050902 hasAuthorship W3166050902A5071891964 @default.
• W3166050902 hasAuthorship W3166050902A5081533954 @default.
• W3166050902 hasAuthorship W3166050902A5085819924 @default.
• W3166050902 hasAuthorship W3166050902A5086753069 @default.
• W3166050902 hasAuthorship W3166050902A5087660180 @default.
• W3166050902 hasAuthorship W3166050902A5089700943 @default.
• W3166050902 hasConcept C121608353 @default.
• W3166050902 hasConcept C126322002 @default.
• W3166050902 hasConcept C143998085 @default.
• W3166050902 hasConcept C185592680 @default.
• W3166050902 hasConcept C203014093 @default.
• W3166050902 hasConcept C2776256026 @default.
• W3166050902 hasConcept C2776706248 @default.
• W3166050902 hasConcept C2776907518 @default.
• W3166050902 hasConcept C2777503454 @default.
• W3166050902 hasConcept C2778164965 @default.
• W3166050902 hasConcept C2779013556 @default.
• W3166050902 hasConcept C44249647 @default.
• W3166050902 hasConcept C515207424 @default.
• W3166050902 hasConcept C55493867 @default.
• W3166050902 hasConcept C71924100 @default.
• W3166050902 hasConcept C8891405 @default.
• W3166050902 hasConceptScore W3166050902C121608353 @default.
• W3166050902 hasConceptScore W3166050902C126322002 @default.
• W3166050902 hasConceptScore W3166050902C143998085 @default.
• W3166050902 hasConceptScore W3166050902C185592680 @default.
• W3166050902 hasConceptScore W3166050902C203014093 @default.
• W3166050902 hasConceptScore W3166050902C2776256026 @default.
• W3166050902 hasConceptScore W3166050902C2776706248 @default.
• W3166050902 hasConceptScore W3166050902C2776907518 @default.
• W3166050902 hasConceptScore W3166050902C2777503454 @default.
• W3166050902 hasConceptScore W3166050902C2778164965 @default.
• W3166050902 hasConceptScore W3166050902C2779013556 @default.
• W3166050902 hasConceptScore W3166050902C44249647 @default.
• W3166050902 hasConceptScore W3166050902C515207424 @default.
• W3166050902 hasConceptScore W3166050902C55493867 @default.
• W3166050902 hasConceptScore W3166050902C71924100 @default.
• W3166050902 hasConceptScore W3166050902C8891405 @default.
• W3166050902 hasIssue "15_suppl" @default.
• W3166050902 hasLocation W31660509021 @default.
• W3166050902 hasOpenAccess W3166050902 @default.
• W3166050902 hasPrimaryLocation W31660509021 @default.
• W3166050902 hasRelatedWork W1974869856 @default.
• W3166050902 hasRelatedWork W2359429907 @default.
• W3166050902 hasRelatedWork W2564916912 @default.
• W3166050902 hasRelatedWork W2743740828 @default.
• W3166050902 hasRelatedWork W2799453846 @default.
• W3166050902 hasRelatedWork W2981133333 @default.
• W3166050902 hasRelatedWork W2995717006 @default.
• W3166050902 hasRelatedWork W3124561726 @default.
• W3166050902 hasRelatedWork W3211406726 @default.
• W3166050902 hasRelatedWork W4221050677 @default.
• W3166050902 hasVolume "39" @default.
• W3166050902 isParatext "false" @default.
• W3166050902 isRetracted "false" @default.
• W3166050902 magId "3166050902" @default.
• W3166050902 workType "article" @default.